Neuronetics (NASDAQ: STIM) director reallocates 42,500 shares to Madryn funds

Rhea-AI Filing Summary

Neuronetics, Inc. director Avinash Amin reported internal share transfers among affiliated investment funds, with no open‑market buying or selling. On 2026-06-15, Amin transferred 4,634 shares of common stock to Madryn Health Partners II, LP, 34,932 shares to Madryn Health Partners II (Cayman Master), LP, and 2,934 shares to Madryn Select Opportunities, LP.

The footnotes state these transfers involved shares received as director compensation and were made for no consideration, as provided in each fund’s partnership agreement. After these J-code restructuring transactions, Amin directly holds 69,566 shares of Neuronetics common stock.

Insights

Insider trading & governance analyst

Filing shows non-cash restructuring transfers of director shares, not market trades.

The Form 4 for Neuronetics, Inc. reports three J-code transactions by director Avinash Amin. These represent transfers of common stock he received as director compensation to three Madryn funds under their partnership agreements, with no cash consideration.

Because these are classified as other acquisitions or dispositions and described as restructuring in the transaction summary, they do not reflect open-market buying or selling. The filing shows Amin holding 69,566 shares directly after the transfers, indicating he continues to maintain a meaningful equity position while reallocating certain shares to the funds.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Amin Avinash

Role null

Type	Security	Shares	Price	Value
Other	Common Stock	2,934	$0.00	--
Other	Common Stock	34,932	$0.00	--
Other	Common Stock	4,634	$0.00	--

Holdings After Transaction: Common Stock — 69,566 shares (Direct, null)

Footnotes (1)

1. The reported transactions involved a transfer of shares received by Avinash Amin as director compensation to each of Madryn Health Partners II, LP ("Health Partners"), Madryn Health Partners II (Cayman Master), LP ("Cayman Master") and Madryn Select Opportunities, LP ("Select Opportunities") as provided for in each fund's respective partnership agreement. Each transfer was made for no consideration. Represents shares of common stock transferred to Health Partners. Represents shares of common stock transferred to Cayman Master. Represents shares of common stock transferred to Select Opportunities.

Key Figures

Shares transferred to Health Partners: 4,634 shares Shares transferred to Cayman Master: 34,932 shares Shares transferred to Select Opportunities: 2,934 shares +2 more

5 metrics

Shares transferred to Health Partners 4,634 shares Common Stock transferred to Madryn Health Partners II, LP on 2026-06-15

Shares transferred to Cayman Master 34,932 shares Common Stock transferred to Madryn Health Partners II (Cayman Master), LP on 2026-06-15

Shares transferred to Select Opportunities 2,934 shares Common Stock transferred to Madryn Select Opportunities, LP on 2026-06-15

Total restructuring transfers 42,500 shares J-code restructuring transactions summarized in transactionSummary

Shares held after transactions 69,566 shares Total Neuronetics common stock directly owned by Amin after transfers

Key Terms

Form 4, director compensation, partnership agreement, J-code, +1 more

5 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

director compensation financial

"transfer of shares received by Avinash Amin as director compensation"

partnership agreement financial

"as provided for in each fund's respective partnership agreement"

A partnership agreement is a written contract that lays out how two or more parties will work together, splitting responsibilities, profits, losses and decision-making. Think of it as a detailed roadmap or house rulebook for a joint project; it matters to investors because the terms determine how much revenue and risk a company will take on, how quickly it can act, and whether the partnership could dilute control or boost growth potential.

J-code regulatory

"These were internal transfers reported under J-code as other acquisition or disposition"

A J-code is a standardized billing code used by U.S. healthcare payers to identify specific injectable or infused drugs and biologic therapies given in clinics or hospitals. For investors, J-codes matter because they determine how treatments are billed and reimbursed by insurers and government programs; having a clear code can make it easier for a medicine to be paid for and for a company to forecast sales, much like a product SKU that allows a store to track and sell an item.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amin Avinash

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		J(1)		2,934(2)	D	$0.00	69,566	D
Common Stock	06/15/2026		J(1)		34,932(3)	D	$0.00	34,634	D
Common Stock	06/15/2026		J(1)		4,634(4)	D	$0.00	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transactions involved a transfer of shares received by Avinash Amin as director compensation to each of Madryn Health Partners II, LP ("Health Partners"), Madryn Health Partners II (Cayman Master), LP ("Cayman Master") and Madryn Select Opportunities, LP ("Select Opportunities") as provided for in each fund's respective partnership agreement. Each transfer was made for no consideration.

2. Represents shares of common stock transferred to Health Partners.

3. Represents shares of common stock transferred to Cayman Master.

4. Represents shares of common stock transferred to Select Opportunities.

	/s/ Avinash Amin	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neuronetics (STIM) director Avinash Amin report?

Director Avinash Amin reported three J-code transactions involving Neuronetics common stock. These were internal transfers of shares he received as director compensation to affiliated Madryn funds, executed for no consideration under the funds’ partnership agreements, rather than open-market purchases or sales.

How many Neuronetics (STIM) shares were transferred in Avinash Amin’s Form 4?

The Form 4 shows restructuring transactions totaling 42,500 Neuronetics common shares. Amin transferred 4,634 shares to Madryn Health Partners II, LP, 34,932 shares to Madryn Health Partners II (Cayman Master), LP, and 2,934 shares to Madryn Select Opportunities, LP, all for no consideration.

Were Avinash Amin’s Neuronetics (STIM) transactions open-market buys or sells?

No, the transactions were not open-market trades. They are J-code “other acquisition or disposition” events, described as transfers of director compensation shares to Madryn funds for no consideration, under each fund’s partnership agreement, rather than discretionary market buying or selling.

How many Neuronetics (STIM) shares does Avinash Amin hold after these transactions?

After the restructuring transfers, the Form 4 reports that Avinash Amin directly holds 69,566 shares of Neuronetics common stock. This post-transaction figure reflects his remaining direct ownership position following the allocation of certain director compensation shares to the Madryn investment funds.

What is the significance of the J transaction code in the Neuronetics (STIM) Form 4?

The J code indicates “other acquisition or disposition” of securities. In this Neuronetics filing, it reflects internal restructuring transfers of director compensation shares to Madryn funds, for no consideration, rather than standard open-market purchases, sales, gifts, or tax-withholding events typically seen with other SEC transaction codes.